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Introduction
Diabetes mellitus (DM) is a heterogeneous group of 
metabolic diseases and can present at any age, from birth to
old age. Transient and permanent neonatal diabetes mellitus
(TNDM and PNDM), which develop within the first few 
weeks or months of life, are very rare conditions with an 
incidence of 1 in 300,000 to 500,000 live births (1,2). TNDM
is a developmental disorder of insulin production that 
resolves in the postnatal period and is mostly associated
with intrauterine growth retardation (2). 50-60% of cases of
neonatal diabetes are TNDM cases, and they recover within
a year. PNDM is less common than the transient form and, in
these patients, insulin dependence is lifelong. Hyperglycaemia,
failure to thrive, and dehydration occur after birth (1). Insulin
production is inadequate, requiring exogenous insulin 
therapy (3). Here, we report a rare case of a patient with
PNDM accompanied by diabetic ketoacidosis (DKA), who
was admitted to the neonatal intensive care unit (NICU) with
suspicion of neonatal sepsis. 
Case Report
A one-month-old boy was referred to the NICU at Kecioren
Training and Research Hospital, Ankara, because of fever,
lethargy, and poor feeding. He was born healthy at 40 
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The birth weight was in the lower limit of the  normal 
range for gestational age (2550 g) and the newborn did not
have any dysmorphic abnormalities at birth. Breastfeeding
was started shortly after delivery. However, frequent stools
were not observed by the family until the patient 
was  admitted to our hospital. He was the first child of 
unrelated parents. There was no family history of diabetes
or autoimmune diseases (Figure 1).
On physical examination, the infant was irritable,
drowsy, approximately 8-10% dehydrated (as estimated by
a sunken fontanelle, sunken eyes and reduced skin turgor),
and tachycardic (176 beats/min). His respiratory rate was 64
breaths/min, body temperature was 39.1°C (rectal), and 
blood pressure was 65/45 mmHg. The source of the fever
was not apparent. First-line laboratory analyses revealed
the following results: Blood chemistry: glucose: 1125
mg/dL, Na: 129 mmol/L, K: 5.1 mmol/L, Cl: 94 mmol/L, 
Ca: 10.8 mg/dL, (venous blood gas analysis), pH: 7.36,
HCO3: 5 mEq/L, and pCO2: 9 mmHg; Urinalysis: specific
gravity 1.028, glucose 4+, ketones 3+. Serum insulin level
was 0.9 μU/mL and C-peptide 0.5 ng/mL, while blood sugar
was 1132 mg/dL at this time. The glycosylated hemoglobin
level (high-pressure liquid chromatography method, HPLC)
was high (10.6%). Anti-insulin, anti-islet cell and anti-glutamic
acid decarboxylase antibodies were found to be negative.
Fecal fat was negative. Thyroid function tests (TSH:
2.1 μU/mL, fT4: 1.02 ng/dL) were within normal ranges. 
Cranial ultrasonography and computed tomography were
normal. Imaging study of the abdomen (i.e. magnetic 
resonance imaging) showed hypoplastic pancreatic tissue.
Echocardiography revealed no abnormality. The parents' 
fasting blood glucose levels were normal. 
A diagnosis of DKA was made and treatment was started
with intravenous insulin (0.05 IU/kg/hour for 2 hours and 0.1
IU/kg/hour thereafter) and a rehydration solution. Insulin
and glucose concentrations were subsequently adjusted 
according to the rate of glucose fall, and no complications
were observed. Hyperglycaemia and ketoacidosis resolved
by the 14th hour of treatment. Breastfeeding was resumed
with feedings at three-hour intervals.  Insulin treatment was
continued with subcutaneous neutral protamine hagedorn
(NPH) (0.8 IU/kg/day in 4 doses) insulin. Following the start
of breastfeeding, we observed watery, loose, yellow-green
colored, and frequent (8-10 times a day) stools, which 
contained no blood or mucus. Although fecal fat was 
negative, pancreatic enzyme replacement therapy was 
initiated due to the frequent stools and finding of pancreatic
hypoplasia on imaging studies.Replacement of pancreatic 
enzymes (40 droplets/HPF) resulted in decreased stool 
frequency (2-4 times a day).
The infant was discharged 3 weeks after admission. 
During the follow-up, insulin dose was decreased (from 4
doses of NPH to 2 doses of NPH), but increased again, 
due to  increment in blood glucose levels to 200-350 mg/dL,
suggesting a diagnosis of PNDM.
Currently, the patient is ten months old and is on two
doses of NPH (0.25 IU/kg/day). His most recent HbA1c 
level was 7.4%. 
Discussion
PNDM is less common than TNDM and never goes into
remission  (2). It accounts for approximately 40-50% of 
neonatal DM cases (4). There are no clinical features that
can predict whether a neonate with diabetes without any
dysmorphology will eventually have PNDM or TNDM (2).
Metz et al (5) showed that PNDM was less likely to be 
associated with  intrauterine growth restriction compared
to TNDM. However, severe intrauterine growth retardation
has been reported in PNDM associated with pancreatic
agenesis (6). Our case had pancreatic hypoplasia, and his
birth weight was on the lower limit of normal range. 
The etiology of neonatal DM is unclear and its 
pathogenesis differs from insulin-dependent childhood DM.
Presence of islet cell antibodies has not been reported in
neonatal DM (7). Anti-insulin, anti-islet cell and anti-glutamic
acid decarboxylase antibodies were also negative in our 
patient.
A number of syndromic and genetic constellations, such
as Wolcott-Rallison syndrome (autosomal recessive), immune
dysregulation, polyendocrinopathy, enteropathy, X-linked
(IPEX) syndrome (X-linked, recessive), phosphoribosyl-ATP
pyrophosphate hyperactivity (X-linked), and glucokinase 
deficiency (MODY2) have been reported in PNDM (2,4).
Wolcott-Rallison syndrome is characterized by the appearance
of PNDM within the first few weeks of life. It is also related
with multiple epiphyseal or spondylo-epiphyseal dysplasia,
cardiac anomaly, recurrent hepatitis, and ectodermal dysplasia
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Figure 1. Pedigree of the patient’s family
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(1,4,8). The other associated syndrome is IPEX, the major 
clinical signs of which are early-onset insulin-dependent DM,
chronic diarrhea with villous atrophy, eczema, anaemia,
thrombocytopenia, severe enteropathy, and eventually other
endocrinopathies (9). In our patient, there were no signs of
the above-mentioned abnormalities.
Pancreatic agenesis/hypoplasia is a clinical entity, which
develops due to mutations in insulin promoter factor-1 (IPF-1)
gene and pancreas transcription factor 1 alpha (PTF1A) (1). It
may be associated with other abnormalities such as cerebellar
hypoplasia, cardiac septal defects or absence of the gallbladder
(10,11). Investigations for presence of other abnormalities in
our patient revealed normal results. In addition, pancreatic
agenesis/hypoplasia is characterized with early-onset PNDM
with no ketoacidosis or signs of malabsorption due to 
pancreatic exocrine dysfunction. In our case, we have 
observed pancreatic hypoplasia on imaging studies. Frequent
stools following breastfeeding also suggested an associated
pancreatic exocrine deficiency. Frequent stools may not be
observed immediately after birth and may be delayed up to
one month of age (12), as seen in our patient.
It was reported that especially in TNDM, ketonuria is
usually mild or absent; but DKA may develop when the 
diagnosis is delayed (1,4,6,13). Wooley et al (4) emphasized
in a case report that these children may present to 
emergency departments with a picture mimicking sepsis,
just like in our case.  We think that the cause of DKA in our
case was due to delayed diagnosis or late admission to the
emergency unit.
Insulin therapy is crucial in neonatal DM to obtain satis-
factory weight gain and growth in these infants. A variety of
methods for providing insulin such as: intravenous infusion,
short-acting and long-acting subcutaneous injections, or
continuous subcutaneous insulin infusion (CSII) can be
used (4). In a study by Mitamura et al (14), control of the 
blood glucose concentration in infants with TNDM was 
attained with ultralente insulin treatment without any episodes
of hypoglycaemia. These authors recommended subcutaneous
injection of ultralente insulin, rather than lente or isophane
(NPH) insulin to avoid hypoglycaemia during treatment. In
recent publications, although there is currently no licence
for its use in this age group, insulin glargine treatment is
suggested, because of its flat pharmacokinetic profile
which might prove useful in this condition (15). In some
centres in Europe, the use of CSII in all cases of neonatal
DM is proposed, stating that during the neonatal period,
CSII therapy is safe, more physiological, more accurate and
easier to manage than injections (16). Due to the existing
controversies about the treatment option,  most cases of
neonatal DM were treated with NPH (4,6,13).In our case,
blood glucose levels were successfully controlled with 2-4
daily doses of NPH insulin treatment, and no serious 
complications have been observed. 
In conclusion, pancreatic hypoplasia is a rare cause of
neonatal DM and is not always associated with intrauterine
growth retardation. Also, neonatal DM due to pancreatic
hypoplasia and associated with DKA may mimic sepsis and
should be kept in mind in all newborns who present with 
fever, dehydration, and weight loss. These patients can be
successfully treated with NPH given in 2-4 doses per day.  
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